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A National Awareness and Early Diagnosis Initiative (NAEDI) has been established in England as part of the Government’s strategy to
improve cancer outcomes. One of the early priorities for this initiative has been to assemble the diverse evidence linking late
diagnosis with poor survival and avoidable deaths. This supplement brings together new perspectives on existing research in this area
together with findings from recently commissioned research. This paper describes a provisional model, the ‘NAEDI pathway’, for
testing hypotheses relating to late diagnosis and its impact. Key findings from other papers in this supplement are also highlighted.
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One of the key commitments of the Cancer Reform Strategy
(2007) (Department of Health, 2007) in England was to establish
a National Awareness and Early Diagnosis Initiative (NAEDI).
This initiative was launched in November 2008 and is co-led by
the Department of Health and Cancer Research UK, with
involvement of a wide range of other stakeholders, including the
research community. The Cancer Reform Strategy recognised that
excellent progress had been made on early detection of cancer
through screening, but more needs to be done to promote early
diagnosis in the large majority of patients who present with
symptoms.
Members of the NAEDI steering group have identified multiple
strands of evidence linking the poor cancer survival rates observed
in the United Kingdom in the EUROCARE studies (Sant et al, 2003,
2009; Berrino et al, 2007) to advanced stage at diagnosis and to
delays occurring between the onset of symptoms and the start of
treatment. However, the evidence base is complex and is still
incomplete.
The aim of this supplement to the British Journal of Cancer is to
bring together as many of these strands as possible and to present
new evidence relevant to NAEDI. It is hoped that this will inform
both the future research agenda and the actions of policy makers
and commissioners at national and local levels.
THE NAEDI PATHWAY
To assist thinking about the issues related to late diagnosis of
cancer, members of the NAEDI steering group have adopted
a provisional ‘NAEDI pathway’ (Figure 1). This should provide a
framework for testing various hypotheses regarding late diagnosis
and its impact. The first step in the pathway proposes that low
awareness of the signs and symptoms of cancer among the public
in general, or in specific subgroups, combined with negative beliefs
about cancer will lead to late presentation to primary care services
and to low uptake of cancer screening services. In addition to this,
there may be perceived or actual barriers to accessing primary care
services. Ultimately, delayed presentation by patients to primary
care services may result in emergency presentations to hospital.
The second step in the pathway involves delays occurring within
primary care. These may occur for a variety of reasons, including
failure to consider cancer as a possible diagnosis and having
inadequate access to diagnostic tests to confirm or exclude cancer
as the underlying cause of a patient’s symptoms. The difficulties
that general practitioners face in this regard should not be
underestimated. In England, an average GP will see seven or eight
new cases of cancer (excluding non-melanoma skin cancer) each
year, but will see hundreds, or possibly thousands, of patients with
symptoms that could possibly be due to cancer. When should the
GP reassure, observe, request investigations or refer to specialist
services?
Delays following referral to specialist services have been well
documented in the United Kingdom, with major efforts being
made to streamline services to achieve defined waiting time
targets. However, relatively little work has been undertaken to
measure the relative contributions of patient delay, doctor delay
and system delay to overall delay for different cancer sites in this
country. Studies of this type have, however, been undertaken in
Denmark, another country with survival rates below the European
average. A paper in this supplement summarises the findings from
Denmark (Olesen et al, 2009).
The key hypothesis underpinning NAEDI is that delays lead to
patients being diagnosed with more advanced disease and thus
experiencing poor 1-year and 5-year survival rates, resulting in
deaths that could potentially have been avoided. This could
potentially account for at least some of the differences in outcomes
observed within the United Kingdom between rich and poor
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ethnic populations and Caucasians (Jack et al, 2009). It could
also account for the differences in survival observed between the
United Kingdom and other comparable western European countries.
Although to many people this sequence accords with common
sense, with the exception of breast cancer (Richards et al, 1999),
the linkage between delay and poor survival has been difficult to
prove from observational studies. Indeed some studies have
reported the apparently paradoxical finding that patients with
longer delays may have better survival rates. How might this be
explained? In most of the reported studies, the nature of the first
symptom has not been reported. It may well be that patients with
the most sinister symptoms in terms of prognosis present rapidly
to health services, while those with other symptoms may still have
early stage disease even after a period of several months. Examples
might include abdominal pain and a mass from a right-sided colonic
cancer, vs rectal bleeding from a more distal cancer – but this still
needs to be tested. In patients with breast cancer, it has been clearly
shown that long patient delays (and overall delays) are associated
with poor survival, while longer doctor delays are associated with
better survival (Afzelius et al, 1994). The logical explanation for this
is that doctors fast track patients with more obvious and advanced
breast cancers (Afzelius et al, 1994). The paper by Neal (2009) sets
out the issues more fully.
THIS SUPPLEMENT OF THE BRITISH JOURNAL OF
CANCER
This supplement brings together evidence related to each step on
the NAEDI pathway from a diverse range of researchers. These
include behavioural scientists, experts in social marketing, public
health physicians, primary care academics and epidemiologists.
Stubbings et al (2009) describe the development and validation
of a new tool to measure public awareness of the signs and
symptoms of cancer – the cancer awareness measure (CAM). This
tool also includes questions about the barriers to seeking medical
help, which may be emotional (e.g. too scared), practical (e.g. too
busy) and/or service barriers (e.g. difficult to make an appoint-
ment). In the following paper (Robb et al, 2009), the first results
using the CAM tool are presented. This population-based survey of
over 2000 adults showed that awareness of the warning signs of
cancer was low when open-ended questions were used. Awareness
was lower in those who were male, younger and from low socio-
economic status groups or ethnic minorities. In a third paper
related to the CAM, the results of using the tool in 1500 men and
women from six minority ethnic groups in England are presented
(Waller et al, 2009). The findings show low awareness across the
group as a whole and important differences between ethnic groups,
with some striking differences from those shown in the popula-
tion-based survey using the same tool (Robb et al, 2009).
A systematic review of the world literature related to interven-
tions aimed at promoting earlier presentation by cancer patients
shows both the paucity of previous research in this field and the
lack of evidence-based approaches to promote early presentation
for any cancer type (Austoker et al, 2009).
In this supplement, two encouraging new approaches to
promote earlier presentation are, however, presented. The first
describes the development and evaluation of a one-to-one
intervention designed to promote early presentation in older
women with breast cancer (Linsell et al, 2009) – a group where
patient delay has been shown to be a particular problem (Ramirez
et al, 1999). The intervention is being tested among women aged
around 70 years who are attending their final routine breast
screening appointment. Screening uptake rates in this age group
are around 70%, so this approach potentially reaches a large
proportion of the older population. The intervention involves a
10-minute interaction with a radiographer. In comparison with
women who received usual care or a booklet alone, those who
received the interaction and a booklet were more breast aware both
at 1 month and 12 months after intervention.
The early findings from a community-based intervention aimed
at raising awareness of the signs and symptoms of three common
cancers (breast, colorectal and lung) and thus at promoting earlier
presentation are presented (Lyon et al, 2009). The programme has
been tested in subpopulations within Primary Care Trusts with high
levels of deprivation. Engagement of local people over the age of
50 years through events in pubs, clubs, mosques, supermarkets and
so on is an important component of this programme. Engagement
of local GPs is also critical. Preliminary findings are encouraging,
especially with respect to the increasing number of cancer cases
being referred through the urgent route, though it is too early to be
definitive about the impact of the programme (Lyon et al, 2009).
The potential for screening to reduce mortality from breast,
cervical and bowel cancer has been well established through
randomised controlled trials. The effectiveness of a national
programme does, however, depend on rates of participation. The
factors known to be associated with low participation in screening
are reviewed (Weller and Campbell, 2009), along with the evidence
of the effectiveness of interventions to promote uptake/coverage.
New evidence related to socio-economic inequalities in the uptake
of faecal occult blood testing for bowel cancer within London is
presented by von Wagner et al (2009).
Uptake of national screening programmes for breast and
cervical cancer is also known to be low in London. Eilbert et al
(2009) report on an innovative whole-systems approach to tackle
low uptake of breast screening in Tower Hamlets – a deprived area
in East London. The approach draws on existing literature about
effective interventions to promote breast screening, combined with
new analyses to understand the specific problems in Tower
Hamlets. A whole-systems approach to improving uptake was then
tested. A campaign targeted at Bangladeshi women was under-
taken, together with a range of initiatives to promote breast
screening through primary care services. The breast screening
service itself was also upgraded. Preliminary findings indicate
significant improvements both in processes and uptake (which has
risen from 44.5% to 58.1%). Further improvements can be
anticipated as a result of recently introduced interventions.
The Bangladeshi community in Tower Hamlets has a high rate
of tobacco and areca nut usage, leading to an increased risk of oral
cancer. Awareness of cancer is also very low in this population. To
tackle this, Cancer Research UK has piloted an awareness raising
and screening programme using a mobile dental unit (Nunn et al,
2009). Over 1300 people attended 1 of 34 screening days (i.e. about
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Figure 1 The NAEDI pathway.
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service. Five patients were diagnosed with dysplasia and a further
28 had potentially malignant disorders (such as leukoplakia). The
feasibility of the approach has been demonstrated.
A contrasting approach that also aims to promote awareness
and early detection of mouth cancer is reported by Eadie et al
(2009). This was targeted at people over 40 years from lower socio-
economic groups in the West of Scotland. A social marketing
approach was adopted, getting people to tell their own stories
using mass media. The aim was to increase people’s feelings of
personal risk, while enhancing feelings of efficacy and control.
Assessments conducted after the campaign indicated that
awareness of three important symptom features (ulcers, changes
that persist and changes to the tongue) was higher in the
intervention area than in a control area both at 7 and 12 months.
Research led by primary care physicians into early diagnosis of
cancer has grown considerably in strength in recent years.
Hamilton (2009) has conducted a series of research studies (the
CAPER studies), investigating delays in diagnosis of cancer from a
primary care perspective. Importantly, these studies identify the
positive predictive value of different symptoms and groups of
symptoms. These findings should form the basis for a more
rational approach to investigation and referral in the future. The
benefits of introducing audits of cancer diagnosis in primary care
in Scotland are described by Baughan et al (2009). Macleod et al
(2009) present an overview of what is known about risk factors for
patient and GP delay from the world literature.
Two important and complementary analyses based on the
EUROCARE-4 data are presented (Møller et al, 2009; Thomson and
Forman, 2009). These re-emphasise the fact that 1-year survival
rates are poor in the United Kingdom across a wide range of
cancers. It is widely agreed that, at least for some cancers, poor
1-year survival is a proxy for patients having advanced stage of
cancer at diagnosis. Interestingly, among patients who survive for
at least 1 year in England, the prospects of surviving to 5 years
seem to be closer to the European average. This provides support
to the hypothesis that late diagnosis is a significant part of the
problem underlying the poor survival rates in this country.
Another important insight into the EUROCARE findings is
provided by Abdel-Rahman et al (2009), who have estimated how
the poor survival rates for individual cancers in the United
Kingdom translate into ‘avoidable deaths’. Their analysis indicates
that around 11000 premature deaths per annum might have been
avoided if survival rates in England had matched the best in
Europe. Against a background of around 125000–130000 deaths
from cancer each year, this is a very significant figure.
Furthermore, around half of these avoidable deaths related to
three cancer types: breast, colorectal and lung.
The study by Abdel-Rahman et al (2009) does not attempt to
quantify what proportion of these avoidable deaths can be
attributed to late diagnosis. In the final article in this supplement,
this is further explored with particular reference to breast,
colorectal and lung cancers (Richards, 2009). We examine the
likelihood of differences in screening or treatment (surgery,
radiotherapy or chemotherapy) accounting for these avoidable
deaths. Although it is impossible to calculate precise figures, we
conclude that a large proportion of the avoidable deaths are likely
to relate to late diagnosis and to patients therefore not receiving
potentially curative treatments. The size of the prize if we can
promote awareness and early diagnosis is very substantial.
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